I'm sure I saw something about this here but can't find it!
Source: Action for ME
Date: July 24, 2017
URL:
https://www.actionforme.org.uk/news/nice-guidelines-on-cfs/m.e.-must-be-reviewed/
NICE guidelines on CFS/M.E. must be reviewed
--------------------------------------------
Action for M.E. has told the National Institute for Health and Care
Excellence (NICE) that the guideline CFS/M.E.: diagnosis and management
must be reviewed in full and updated.
NICE have proposed not updating the guideline, which recommends that
patients are offered CBT and GET, based on their surveillance review of
evidence published since 2007.
Our response to their consultation states:
* there is not a conclusive evidence base for treatments for M.E.,
including those recommended in the guideline, such as cognitive
behaviour therapy (CBT) and/or graded exercise therapy (GET).
* the current evidence base has led major international health agencies,
including the Centers for Disease Control and Prevention in the US, to
alter their guidance regarding CBT and GET.
* NICE has an ethical obligation to present a full, accurate and
balanced picture of current international clinical practice when it
comes to managing and treating M.E.
This decision would have serious implications for patients’ access to
medical care. Retaining the 2007 guideline would mean that:
* clinicians would not be informed of the inconclusive and disputed
nature of the evidence on the effectiveness of CBT and GET
* therefore patients will not have equal access to other healthcare that
could benefit their health, such as pharmacological treatments or other
symptom management approaches.
As part of its consultation, NICE asked for feedback on a proposal to
remove the NICE guideline from its static list, and review it at more
frequent two-year intervals. Action for M.E. support this decision,
given that current and upcoming research may impact on NICE
recommendations in the near future. Examples include ongoing research
into an antiviral, valganciclovir, as well as a current phase-III trial
into the immunosuppressant Rituximab.
As well as sending our own response, Action for M.E. collaborated with
the Countess of Mar and other M.E. organisations as part of Forward M.E.
to submit an agreed joint response. This highlights the ethical duty of
NICE to respect patient choice and to ensure patients have access to
biological medical care.
--------
(c) 2017 AfME
Source: Action for ME
Date: July 24, 2017
URL:
https://www.actionforme.org.uk/news/nice-guidelines-on-cfs/m.e.-must-be-reviewed/
NICE guidelines on CFS/M.E. must be reviewed
--------------------------------------------
Action for M.E. has told the National Institute for Health and Care
Excellence (NICE) that the guideline CFS/M.E.: diagnosis and management
must be reviewed in full and updated.
NICE have proposed not updating the guideline, which recommends that
patients are offered CBT and GET, based on their surveillance review of
evidence published since 2007.
Our response to their consultation states:
* there is not a conclusive evidence base for treatments for M.E.,
including those recommended in the guideline, such as cognitive
behaviour therapy (CBT) and/or graded exercise therapy (GET).
* the current evidence base has led major international health agencies,
including the Centers for Disease Control and Prevention in the US, to
alter their guidance regarding CBT and GET.
* NICE has an ethical obligation to present a full, accurate and
balanced picture of current international clinical practice when it
comes to managing and treating M.E.
This decision would have serious implications for patients’ access to
medical care. Retaining the 2007 guideline would mean that:
* clinicians would not be informed of the inconclusive and disputed
nature of the evidence on the effectiveness of CBT and GET
* therefore patients will not have equal access to other healthcare that
could benefit their health, such as pharmacological treatments or other
symptom management approaches.
As part of its consultation, NICE asked for feedback on a proposal to
remove the NICE guideline from its static list, and review it at more
frequent two-year intervals. Action for M.E. support this decision,
given that current and upcoming research may impact on NICE
recommendations in the near future. Examples include ongoing research
into an antiviral, valganciclovir, as well as a current phase-III trial
into the immunosuppressant Rituximab.
As well as sending our own response, Action for M.E. collaborated with
the Countess of Mar and other M.E. organisations as part of Forward M.E.
to submit an agreed joint response. This highlights the ethical duty of
NICE to respect patient choice and to ensure patients have access to
biological medical care.
--------
(c) 2017 AfME